Literature DB >> 17538890

Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.

Katherine L O'Brien1, Jennifer Moisi, Lawrence H Moulton, Dace Madore, Angelia Eick, Ray Reid, Robert Weatherholtz, Eugene Millar, Diana Hu, Jill Hackell, Robert Kohberger, George Siber, Mathuram Santosham.   

Abstract

BACKGROUND: Pneumococcal conjugate vaccines are important for the prevention of serious illness and death among infants. Factors associated with pneumococcal conjugate vaccine immunogenicity have not been explored.
METHODS: Children <24 months of age received 2, 3, or 4 doses of 7-valent pneumococcal conjugate vaccine (PnCRM7) or control vaccine depending on age at enrollment. Serum samples were tested for serotype-specific antibodies by enzyme-linked immunosorbant assay. Multiple linear regression was used to determine predictors of immunogenicity.
RESULTS: Among 315 PnCRM7-vaccinated subjects and 295 control subjects enrolled at <7 months of age, geometric mean concentrations (GMCs) of antibodies were significantly higher after dose 3 than after dose 2 for all serotypes except type 4. The proportion of subjects with antibody concentrations > or =5.0 micro g/mL was higher for all serotypes, but the proportion with concentrations > or =0.35 micro g/mL was higher only for types 6B and 23F. Three-dose and 2-dose regimens for those 7-11 and 12-23 months of age, respectively, were highly immunogenic. Increased maternal antibody concentrations were associated with reduced responses to dose 1 and 3 but not to dose 4 of PnCRM7.
CONCLUSIONS: Maternal antibody is associated with a reduced infant response to PnCRM7 but does not interfere with immune memory. In infants, a third priming dose increases the antibody GMC and the proportion achieving an antibody concentration > or =5.0 micro g/mL but has little impact on the proportion achieving a concentration > or =0.35 micro g/mL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17538890     DOI: 10.1086/518438

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis.

Authors:  Merryn Voysey; Dominic F Kelly; Thomas R Fanshawe; Manish Sadarangani; Katherine L O'Brien; Rafael Perera; Andrew J Pollard
Journal:  JAMA Pediatr       Date:  2017-07-01       Impact factor: 16.193

2.  Maternal pneumococcal capsular IgG antibodies and transplacental transfer are low in South Asian HIV-infected mother-infant pairs.

Authors:  Amita Gupta; Jyoti S Mathad; Wei-Teng Yang; Harjot K Singh; Nikhil Gupte; Vidya Mave; Renu Bharadwaj; K Zaman; Eliza Roy; Robert C Bollinger; Ramesh Bhosale; Mark C Steinhoff
Journal:  Vaccine       Date:  2014-01-30       Impact factor: 3.641

3.  Immune responses of female BALB/c and C57BL/6 neonatal mice to vaccination or intestinal infection are unaltered by exposure to breast milk lycopene.

Authors:  Becky Adkins; Nikhat Contractor
Journal:  J Nutr       Date:  2011-05-18       Impact factor: 4.798

4.  Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization.

Authors:  Shabir A Madhi; Avy Violari; Keith P Klugman; Gina Lin; James A McIntyre; Anne von Gottberg; Patrick Jean-Philippe; Mark F Cotton; Peter Adrian
Journal:  Vaccine       Date:  2011-07-23       Impact factor: 3.641

5.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

6.  Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine.

Authors:  Paul Balmer; Ray Borrow; Jamie Findlow; Rosalind Warrington; Sarah Frankland; Pauline Waight; Robert George; Nick Andrews; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2007-09-19

7.  Enhanced immunogenicity of a bivalent nicotine vaccine.

Authors:  D E Keyler; S A Roiko; C A Earley; M P Murtaugh; P R Pentel
Journal:  Int Immunopharmacol       Date:  2008-07-24       Impact factor: 4.932

8.  Randomized, single blind, controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in renal transplant recipients.

Authors:  Selma Tobudic; Veronika Plunger; Gere Sunder-Plassmann; Markus Riegersperger; Heinz Burgmann
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

9.  Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.

Authors:  Lindsay R Grant; Sarah E O'Brien; Polly Burbidge; Mitch Haston; Marta Zancolli; Lucy Cowell; Marina Johnson; Robert C Weatherholtz; Raymond Reid; Mathuram Santosham; Katherine L O'Brien; David Goldblatt
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

10.  Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.

Authors:  Laura L Hammitt; John Ojal; Mahfudh Bashraheil; Susan C Morpeth; Angela Karani; Ahsan Habib; Dorota Borys; David Goldblatt; J Anthony G Scott
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.